Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TALIMOGENE LAHERPAREPVEC
- oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection
- TVEC and Preop Radiation for Sarcoma (8 ml Dose)
- Neoadjuvant T-VEC in High Risk Early Melanoma
- Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
- Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma
- Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
- Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
- Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
- Neoadjuvant Combination Immunotherapy for Stage III Melanoma
- Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer
- Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
- Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
- A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
- TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Locoregionally Recurrent HER2- Negative Breast Cancer
- Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
- Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
- Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
- A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
- A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
- Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
- Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
- Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence
- Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
- Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
- TVEC and Preop Radiation for Sarcoma (4 ml Dose)
- Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
- Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
- PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
- Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)
- Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
- Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
- Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
- Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
- An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
- Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
- A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
Clinical trials list
click for details